Clinical trial
Treatment for Subjects With Chronic Kidney Disease Receiving Haemodialysis
NCT00116701 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00116701 |
|---|---|
| Title | Treatment for Subjects With Chronic Kidney Disease Receiving Haemodialysis |
| Official title | A Study to Evaluate the Efficacy of Converting From Intravenous or Subcutaneous rHuEPO to Intravenous Darbepoetin Alfa (Aranesp®) in Subjects With Chronic Kidney Disease Receiving Haemodialysis |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Kidney Disease |
| Intervention type | Drug |
| Interventions | Aranesp® |
| Enrollment | 200 |
| Start date | May 1, 2005 |
| First posted | Jul 1, 2005 |
| Last update posted | May 5, 2008 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: